Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
entities : Pfizer, inc. save search
Global Peptide Antibiotics Market Report 2022: Sector to Reach $5.74 Billion in 2026 at a CAGR of 8%
Published: 2023-03-28 (Crawled : 01:00) - prnewswire.com
GLAXF | $20.2 -14.18% 510
|
Health Technology
|
| O: 3.17%
H: 0.0%
C: 0.0%
PFE A | $25.39 -0.12% -0.12% 36M
|
Health Technology
|
| O: -0.05%
H: 0.25%
C: -0.52%
NVS | $92.57 -0.55% 0.0% 910K
|
Health Technology
|
| O: -0.38%
H: 1.25%
C: 1.12%
GSK | $39.27 -0.83% 0.01% 2.2M
|
Health Technology
|
| O: 0.26%
H: 0.17%
C: -0.09%
LLY | $745.95 -0.64% -0.1% 1.7M
|
Health Technology
|
| O: 0.36%
H: 0.9%
C: 0.55%
SNY | News | $45.395 -1.55% -1.58% 4.4M
|
Health Technology
|
| O: 2.06%
H: 0.0%
C: 0.0%
report antibiotics global market
Novartis Kisqali® Phase III NATALEE trial meets primary endpoint at interim analysis demonstrating clinically meaningful benefit in broad population of patients with early breast cancer
Published: 2023-03-27 (Crawled : 06:00) - globenewswire.com
PFE A | $25.39 -0.12% -0.12% 36M
|
Health Technology
|
| O: 0.37%
H: 0.2%
C: -0.79%
NVS | $92.57 -0.55% 0.0% 910K
|
Health Technology
|
| O: 6.51%
H: 1.75%
C: 1.4%
kisqali breast cancer novartis trial
Phase 3 Study Shows XTANDI® (enzalutamide) plus Leuprolide Significantly Improves Metastasis-Free Survival in Men with Non-Metastatic Prostate Cancer
Published: 2023-03-16 (Crawled : 00:00) - prnewswire.com
ALPMY | $9.46 -1.11% 500K
|
Manufacturing
|
| O: -0.18%
H: 0.25%
C: 0.25%
PFE A | $25.39 -0.12% -0.12% 36M
|
Health Technology
|
| O: 0.63%
H: 0.41%
C: -1.29%
xtandi cancer plus study
Pyxis Oncology Announces Dosing of First Subject in Phase 1 Trial of PYX-201, a Novel ADC for Solid Tumors
Published: 2023-03-16 (Crawled : 12:20) - biospace.com/
PYXS | $4.51 -6.63% -7.1% 470K
|
Professional, Scientific, and T...
|
| O: 0.0%
H: 7.46%
C: 7.46%
PFE A | $25.39 -0.12% -0.12% 36M
|
Health Technology
|
| O: -0.55%
H: 1.07%
C: 0.77%
pyx-201 tumors trial phase 1
Astellas Announces Phase 3 China ARCHES Study of XTANDI® Meets Primary Endpoint
Published: 2023-03-13 (Crawled : 00:00) - prnewswire.com
ALPMY | $9.46 -1.11% 500K
|
Manufacturing
|
| O: 1.01%
H: 0.43%
C: 0.29%
PFE A | $25.39 -0.12% -0.12% 36M
|
Health Technology
|
| O: 0.48%
H: 0.25%
C: -0.37%
xtandi china study
Pfizer Invests $43 Billion to Battle Cancer
Published: 2023-03-13 (Crawled : 12:00) - biospace.com/
PFE A | $25.39 -0.12% -0.12% 36M
|
Health Technology
|
| O: -0.34%
H: 3.18%
C: 1.54%
SGEN | $228.74 0.1% 20M
|
Health Technology
|
| O: 15.14%
H: 2.07%
C: -0.55%
SNY | News | $45.395 -1.55% -1.58% 4.4M
|
Health Technology
|
| O: -0.81%
H: 0.0%
C: 0.0%
cancer
Pfizer’s ZAVZPRET™ (zavegepant) Migraine Nasal Spray Receives FDA Approval
Published: 2023-03-10 (Crawled : 12:20) - biospace.com/
PFE A | $25.39 -0.12% -0.12% 36M
|
Health Technology
|
| O: -0.43%
H: 1.63%
C: 0.25%
fda spray approval migraine
Voyager Therapeutics Reports Fourth Quarter and Full Year 2022 Financial and Operating Results
Published: 2023-03-07 (Crawled : 12:00) - ir.voyagertherapeutics.com
PFE A | $25.39 -0.12% -0.12% 36M
|
Health Technology
|
| O: -0.12%
H: 0.17%
C: -1.75%
VYGR | $7.55 -2.46% -2.52% 1M
|
Health Technology
|
| O: 0.63%
H: 0.12%
C: -8.36%
NBIX M | $132.49 -0.56% -0.56% 550K
|
Health Technology
|
| O: 0.16%
H: 0.0%
C: -2.54%
year therapeutics financial results
Avanos Medical, Inc. Appoints Dr. Lisa Egbuonu-Davis to Board of Directors
Published: 2023-03-06 (Crawled : 14:00) - biospace.com/
PFE A | $25.39 -0.12% -0.12% 36M
|
Health Technology
|
| O: -0.15%
H: 0.41%
C: 0.05%
DHR | $236.36 -1.27% 0.0% 4.2M
|
Health Technology
|
| O: -0.39%
H: 0.9%
C: -0.92%
AVNS | $18.7 -0.05% 0.0% 290K
|
Health Technology
|
| O: -0.07%
H: 0.19%
C: -2.57%
SNY | News | $45.395 -1.55% -1.58% 4.4M
|
Health Technology
|
| O: 0.67%
H: 0.0%
C: 0.0%
Pfizer Receives Positive FDA Advisory Committee Votes Supporting Potential Approval for Vaccine Candidate to Help Combat RSV in Older Adults
Published: 2023-02-28 (Crawled : 00:00) - biospace.com/
PFE A | $25.39 -0.12% -0.12% 36M
|
Health Technology
|
| O: -0.69%
H: 0.52%
C: 0.17%
fda candidate vaccine rsv approval potential positive
The Worldwide Inhalable Drugs Industry is Expected to Reach $49.47 Billion by 2027: Players Include AptarGroup, AstraZeneca, Cipla, GEA and GSK
Published: 2023-02-28 (Crawled : 04:00) - prnewswire.com
NVSEF | $93.6375 6.88% 82K
|
Health Technology
|
| O: -2.64%
H: 0.0%
C: -0.1%
PFE A | $25.39 -0.12% -0.12% 36M
|
Health Technology
|
| O: -0.69%
H: 0.52%
C: 0.17%
NVS | $92.57 -0.55% 0.0% 910K
|
Health Technology
|
| O: -0.48%
H: 0.05%
C: -1.2%
ATR | $139.11 0.51% 0.0% 240K
|
Process Industries
|
| O: -0.03%
H: 1.25%
C: 0.06%
TFFP | $3.2405 -9.69% 26K
|
Health Technology
|
| O: 0.01%
H: 12.67%
C: 6.65%
SNY | News | $45.395 -1.55% -1.58% 4.4M
|
Health Technology
|
| O: -1.4%
H: 0.0%
C: 0.0%
expected
Optic Nerve Disorder Treatment Market to Reach USD 5.3 Billion, Globally, by 2031 at 4.5% CAGR: Allied Market Research
Published: 2023-02-27 (Crawled : 07:00) - prnewswire.com
PFE A | $25.39 -0.12% -0.12% 36M
|
Health Technology
|
| O: -0.74%
H: 0.7%
C: -1.59%
NVS | $92.57 -0.55% 0.0% 910K
|
Health Technology
|
| O: 0.64%
H: 0.01%
C: -0.72%
ABBV | News | $164.66 0.25% -0.15% 4.5M
|
Health Technology
|
| O: 0.36%
H: 0.97%
C: 0.67%
treatment research market
ViiV Healthcare Announces Positive Data Demonstrating Long-acting Injectable Cabenuva (cabotegravir, rilpivirine) is as Effective as Daily Oral Biktarvy (BIC/FTC/TAF) for the Treatment of HIV-1
Published: 2023-02-23 (Crawled : 09:00) - biospace.com/
PFE A | $25.39 -0.12% -0.12% 36M
|
Health Technology
|
| O: -0.21%
H: 1.09%
C: 0.02%
JNJ | News | $145.74 0.67% 0.0% 9.3M
|
Health Technology
|
| O: -0.04%
H: 0.55%
C: 0.01%
treatment biktarvy positive
Pfizer’s Elranatamab Receives FDA and EMA Filing Acceptance
Published: 2023-02-22 (Crawled : 14:00) - biospace.com/
PFE A | $25.39 -0.12% -0.12% 36M
|
Health Technology
|
| O: 0.05%
H: 0.39%
C: -0.8%
fda ema
Antiglaucoma Drugs Global Market Report 2023
Published: 2023-02-20 (Crawled : 18:00) - prnewswire.com
NVSEF | $93.6375 6.88% 82K
|
Health Technology
| Email alert
Add to watchlist
NVS | $92.57 -0.55% 0.0% 910K
|
Health Technology
| Email alert
Add to watchlist
AERI | $15.25 0.0%
|
Health Technology
| Email alert
Add to watchlist
PFE A | $25.39 -0.12% -0.12% 36M
|
Health Technology
| Email alert
Add to watchlist
JNJ | News | $145.74 0.67% 0.0% 9.3M
|
Health Technology
| Email alert
Add to watchlist
global report market
Pfizer and Valneva Issue Update on Phase 3 Clinical Trial Evaluating Lyme Disease Vaccine Candidate VLA15
Published: 2023-02-17 (Crawled : 08:00) - biospace.com/
PFE A | $25.39 -0.12% -0.12% 36M
|
Health Technology
|
| O: -0.14%
H: 1.12%
C: 0.75%
vla15 valneva candidate disease vaccine trial update
Pfizer Announces Positive TALZENNA® and XTANDI® Combination Data from Phase 3 TALAPRO-2 Study
Published: 2023-02-16 (Crawled : 16:00) - biospace.com/
PFE A | $25.39 -0.12% -0.12% 36M
|
Health Technology
|
| O: -0.39%
H: 0.07%
C: -0.46%
talzenna positive study
Global Melanoma Therapeutics Market to Reach $9.5 Billion by 2030
Published: 2023-02-15 (Crawled : 16:00) - prnewswire.com
AZNCF | $140.15 -4.19% 560
|
Health Technology
|
| O: 0.66%
H: 1.9%
C: 1.9%
PFE A | $25.39 -0.12% -0.12% 36M
|
Health Technology
|
| O: -0.69%
H: 0.44%
C: -0.23%
BMY | $48.3 0.96% -0.1% 11M
|
Health Technology
|
| O: 0.07%
H: 0.24%
C: -1.15%
IOVA M | $11.72 -0.68% -0.68% 3.6M
|
Health Technology
|
| O: -0.48%
H: 1.3%
C: -0.34%
AZN | $68.36 -0.25% -0.25% 4M
|
Health Technology
|
| O: -1.28%
H: 0.56%
C: 0.36%
melanoma global therapeutics market
ViiV Healthcare to present first head-to-head data for long-acting HIV treatment Cabenuva against daily oral Biktarvy at CROI 2023
Published: 2023-02-14 (Crawled : 15:00) - biospace.com/
GLAXF | $20.2 -14.18% 510
|
Health Technology
|
| O: 0.74%
H: 2.37%
C: 1.92%
PFE A | $25.39 -0.12% -0.12% 36M
|
Health Technology
|
| O: 0.23%
H: 0.25%
C: -0.84%
GSK | $39.27 -0.83% 0.01% 2.2M
|
Health Technology
|
| O: -0.33%
H: 0.06%
C: -0.14%
treatment hiv biktarvy
Regenerative Medicine Market to be Worth $180.87 Billion by 2030: Grand View Research, Inc.
Published: 2023-02-14 (Crawled : 10:00) - prnewswire.com
AZNCF | $140.15 -4.19% 560
|
Health Technology
|
| O: 0.43%
H: 1.52%
C: -1.88%
NVSEF | $93.6375 6.88% 82K
|
Health Technology
|
| O: 0.34%
H: 0.0%
C: 0.0%
USRM | $0.0001 1300.0% 290K
|
Professional, Scientific, and T...
|
| O: 2.22%
H: 4.35%
C: 4.35%
PFE A | $25.39 -0.12% -0.12% 36M
|
Health Technology
|
| O: 0.23%
H: 0.25%
C: -0.84%
NVS | $92.57 -0.55% 0.0% 910K
|
Health Technology
|
| O: 0.27%
H: 0.42%
C: -0.21%
LLY | $745.95 -0.64% -0.1% 1.7M
|
Health Technology
|
| O: 0.04%
H: 0.93%
C: -0.85%
NUVA | $39.75 -2.24% -2.29% 0
|
Health Technology
|
| O: -0.16%
H: 2.24%
C: 0.79%
MDXG | $6.17 -2.53% -2.59% 540K
|
Health Technology
|
| O: -1.3%
H: 2.85%
C: 2.19%
AZN | $68.36 -0.25% -0.25% 4M
|
Health Technology
|
| O: 0.3%
H: 0.94%
C: 0.6%
AMGN | $262.77 -0.49% -0.49% 2M
|
Health Technology
|
| O: -0.39%
H: 0.12%
C: -0.69%
market
Gainers vs Losers
| 64% | 36% |
Top 10 Gainers
AGBA | News | $1.02 155.0% 57.94% 120M
|
Finance
ZCMD | $2.86 108.76% 52.1% 2.3M
|
Commercial Services
INVO | $1.555 104.6% 51.13% 5M
|
Health Technology
ISPC | $0.437 105.16% 49.53% 37M
|
Professional, Scientific, and T...
WLGS | News | $0.92 84.0% 45.65% 1.6M
|
OST | $0.499 21.38% 45.26% 1.9M
|
XPON | News | $3.1 60.62% 37.74% 17M
|
TIRX | $0.7 44.39% 30.74% 58M
|
BNTC | News | $6.92 44.17% 30.64% 3.5M
|
Health Technology
GGE | $0.035 19.86% 29.3% 64M
|
Your saved searches
Save your searches and get alerts when important news are released.